Lupin has launched Methylergonovine Maleate Tabs USP, 0.2 mg, having received an approval from the United States Food and Drug Administration (USFDA) earlier. Methylergonovine Maleate Tabs USP, 0.2 mg, had annual sales of approximately $71.5 million in the US (IQVIA MAT April 2018).
Lupin’s Methylergonovine Maleate Tabs USP, 0.2 mg, is the generic equivalent of Novartis Pharmaceuticals Corporation’s Methergine. It is indicated for the prevention and control of postpartum hemorrhage.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
